Last reviewed · How we verify
Budesonide pMDI HFA
At a glance
| Generic name | Budesonide pMDI HFA |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- Bioavailability Study of SYN006, Pulmicort pMDI and Meptin Air in Healthy Adult. (PHASE1)
- A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy (PHASE2)
- Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma (PHASE3)
- A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma. (PHASE3)
- An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma (PHASE3)
- Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma (PHASE3)
- Titratable Dosing in Moderate to Severe Asthmatics (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budesonide pMDI HFA CI brief — competitive landscape report
- Budesonide pMDI HFA updates RSS · CI watch RSS
- AstraZeneca portfolio CI